ADAR1 Capital’s Latest Block Buy Signals Confidence in InMed’s Cannabis‑Driven Future【News Flash】

ADAR1 Capital’s Surge in InMed Shares: What Investors Should Know

ADAR1 Capital Management, LLC has added a new block of 564 shares to its InMed portfolio on October 13, 2026, purchasing the shares at $1.33 each for a total of $748.32. The transaction is part of a broader buying spree that has seen the private‑fund manager amass roughly 955,000 shares in the last week, a 16% increase over the prior 10‑day period. The trade coincides with a modest uptick in the stock price (+0.02%) and a positive social‑media sentiment of +10, suggesting that the market is reacting favorably to the influx of capital.

Implications for the Stock and Shareholder Base

The concentrated buying by ADAR1 Capital—already a significant shareholder—raises questions about the direction InMed might be headed. A surge of purchases from a single investor can signal confidence in forthcoming product launches, regulatory approvals, or a restructuring plan. However, the company’s fundamentals remain uneven: a negative price‑earnings ratio of –0.48 and a 52‑week low of $0.58 suggest that earnings are still below expectations. The current market cap of $8.84 M keeps InMed in the micro‑cap segment, meaning that even modest changes in investor sentiment can cause sizable price swings.

What the Trend Means for Investors

For long‑term investors, ADAR1’s activity could be a bellwether for a potential upside if the company’s cannabis‑based pipeline moves forward. The firm’s focus on proprietary platform technology could attract strategic partnerships, especially if the industry continues to liberalize. Short‑term traders may watch for volatility: the 11.19% buzz indicates heightened discussion, and any future insider activity could trigger rapid price corrections. Diversifying holdings or setting clear stop‑loss levels might mitigate risk in this volatile space.

Profile of ADAR1 Capital Management, LLC

ADAR1 Capital’s transaction history shows a pattern of incremental purchases rather than one‑off block buys. Beginning in mid‑May 2026 with a $200,000 purchase at $1.56, the fund steadily increased its stake through late September, buying between 5,000 and 54,000 shares per trade at prices ranging from $1.29 to $1.56. The most recent spree—over 18,000 shares on October 5 and another 5,000 on October 6—demonstrates an aggressive accumulation strategy as the stock approaches its 52‑week high of $2.33. The fund’s holdings, now close to 1.1 M shares, represent a significant percentage of the 6.7 M shares outstanding, giving ADAR1 considerable voting power in any upcoming corporate actions.

Conclusion

ADAR1 Capital’s latest purchase is a subtle but telling indicator of confidence in InMed Pharmaceuticals’ future. While the company’s earnings profile and market cap suggest caution, the recent buying activity—and the positive social‑media buzz—could presage a rally if the biotech’s cannabinoid pipeline delivers. Investors should weigh the potential upside against the inherent volatility of a micro‑cap biotech, keeping a close eye on future insider trades and any regulatory developments that could reshape InMed’s trajectory.